Helpilepsy

What Helpilepsy does

Helpilepsy is a Belgium-based digital health platform operated by Neuroventis BV that targets two interconnected customer segments: people with epilepsy (patients and caregivers) and the neurologists who treat them. The company was founded in 2017 and is headquartered in Overijse, Belgium, with additional offices in Merelbeke-Melle and Brussels. It employs between 11 and 50 people and operates across Belgium, the Netherlands, France, Germany, and Hungary with localized versions in Dutch, French, German, and Hungarian.

The product consists of a free mobile application for patients (available on iOS and Google Play) that enables tracking of seizures, side effects, medication intake, appointments, and lifestyle factors, complemented by a 5-star gamification layer and medication reminders, and a paid web-based professional tier (Helpilepsy PRO) accessible exclusively through partner neurologists. The PRO tier provides neurologists with a structured dashboard for visualizing patient-collected data and supports pre-consultation report generation one week before appointments. The platform is certified as a Class I medical device under EU Directive 93/42/EEC and is co-developed with epileptologists and patient representatives.

The business model is a freemium-plus-prescription hybrid. The patient app is free, generating no direct revenue but building a long-tail user base, while the PRO professional version is sold as an annual subscription to neurologists who prescribe the platform to their patients. Distribution runs through two parallel go-to-market motions: a product-led, app-store-driven funnel for patients and a sales-led, demo-and-onboarding motion for neurologists and hospitals. Named institutional customers include William Lennox Hospital, H.-Hartziekenhuis Lier, UZ Leuven, and CHU, and strategic partners span UCB (biopharma), Imec (R&D), EIT Health, and Bluehealth Innovation Center.

Name

Helpilepsy

Legal name

Neuroventis BV

Website

https://helpilepsy.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Helpilepsy, operated by Belgium-based Neuroventis BV, provides a Class I medical-device epilepsy tracking mobile app for patients and a subscription web dashboard for prescribing neurologists across Belgium, the Netherlands, France, Germany, and Hungary.

Ownership category

akta.pro rank

Product category

Digital Health Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYHLAHACAE

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

SECONDARYHLACANAI

Behavioral Health & Neurocognitive Therapeutics (Digital)

Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

• Epilepsy tracking app
• Digital health platform
• Neurology web dashboard
• Patient seizure diary
• Medical device software

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Freemium Patient App: The basic Helpilepsy mobile app is free for patients with epilepsy. This creates a large user base and bottom-up adoption. Revenue is indirect through conversion to PRO and potential data/insights value.
2. Helpilepsy PRO Subscription: The professional PRO version is not free and is only accessible through partner neurologists. Neurologists subscribe/pay for PRO access to monitor their patients. The exact pricing model is not publicly disclosed.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Helpilepsy operates a dual digital health offering: a free iOS/Android patient app for tracking seizures, side effects, medication, appointments, and lifestyle triggers (with medication reminders, gamified 5-star logging, and pre-consultation report generation), and Helpilepsy PRO — a subscription-only service for partner neurologists that provides a web dashboard for visualizing patient-reported data during consultations. Both components are built on the Neuroventis Platform, certified as a Class I medical device under EU Directive 93/42/EEC.

Product overview

Helpilepsy offers a dual-component digital health platform consisting of a mobile app for patients with epilepsy to track seizures, side effects, medication, and appointments, and a companion web dashboard (Helpilepsy PRO) for neurologists to access and visualize patient data. The platform includes an optional Epilepsy Self-Management Program for structured patient education. The patient app and neurologist dashboard work in tandem to facilitate data sharing during consultations, with pre-appointment reports generated from patient-entered data.

Differentiator

Problem solved

Functional benefit

Products and services

• Helpilepsy App (Patient Mobile App)

Quantifiable outcome

• Patients receive pre-consultation reports one week before appointments summarizing seizures, side effects, treatments, and their questions for the neurologist
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• UCB (Biopharma)minorStrategic or Co-development PartnerUCB (a biopharma company) is shown as a partner organization on the Helpilepsy website, suggesting collaboration in the epilepsy treatment ecosystem. UCB develops epilepsy medications, making this a complementary relationship in the pharmaceutical-digital health intersection.
• EIT HealthcoreStrategic or Co-development PartnerEIT Health (European Institute of Innovation and Technology, Health branch) is shown as a partner. EIT Health supports innovative health tech companies through funding, mentoring, and network access. Helpilepsy's association with EIT Health indicates received support for product development and European market expansion.
• Bluehealth Innovation Center (BHIC)minorStrategic or Co-development PartnerBluehealth Innovation Center (a Belgian healthcare innovation organization) is shown as a partner. BHIC focuses on digital health innovation and likely provides ecosystem support for Helpilepsy's development.
• Neuroventis BVcoreOthersNeuroventis BV is the parent/operating company of Helpilepsy. Helpilepsy is described as 'a component' of the Neuroventis Platform. Neuroventis BV is headquartered at Groeneweg 35A, 3090 Overijse, Belgium (company number 0671.531.790). The platform is classified as a Class I medical device under EU Directive 93/42/EEC.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Epsy: Epsy (formerly Epilepsy Health) offers a mobile app for seizure, medication, and side-effect tracking plus a clinician dashboard, directly overlapping Helpilepsy's patient app and neurologist PRO in functionality and target users (patients with epilepsy and their treating neurologists).
• Seizure Tracker: Seizure Tracker provides seizure logging, medication tracking, and exportable reports for patients and clinicians. It is one of the most established direct competitors in patient-driven epilepsy diary tools, comparable to Helpilepsy's free tracking tier.
• My Seizure Diary (Epilepsy Foundation): My Seizure Diary is a free digital seizure diary offered by the Epilepsy Foundation that lets patients log seizures, medications, and triggers and share data with providers. It overlaps Helpilepsy's core patient tracking and clinician reporting value proposition, particularly in the US market.

Emerging players

• Empatica: Empatica's EpiMonitor is an FDA-cleared wearable for seizure detection that complements clinician decision-making. It overlaps with Helpilepsy in addressing neurologist epilepsy workflows but adds a hardware/sensor layer, making it a partial rather than direct competitor.
• Pear Therapeutics (legacy): Pear Therapeutics was a pioneer in prescription digital therapeutics with regulatory-cleared software therapies. While its portfolio focused on substance use and insomnia rather than epilepsy, it represents the digital therapeutic regulatory and reimbursement path that Helpilepsy's self-management program could pursue.

Broad incumbents

• NeuroPace: NeuroPace commercializes the RNS System, a closed-loop neurostimulation device for refractory epilepsy with a clinician-facing data platform. It serves the same neurologist epilepsy community but at a much higher-acuity interventional segment than Helpilepsy's monitoring/tracking focus.
• LivaNova: LivaNova is a global medical device company active in neuromodulation, including vagus nerve stimulation (VNS) for drug-resistant epilepsy. While its core offering is hardware therapy, it interacts with the same epileptologist customer base and increasingly seeks digital companions to support therapy adherence and outcomes tracking.
• Medtronic: Medtronic operates across neurology and neurosurgery, including deep brain stimulation systems used for movement disorders and adjacent indications. It does not directly compete in seizure diaries but is a broad incumbent that could bundle tracking functionality into its clinician ecosystem if it chose to.

Regional players

• Byteflies: Byteflies is a Belgium-based wearable health monitoring company providing clinical-grade sensor solutions for neurology and remote patient monitoring trials. It shares Helpilepsy's Belgian roots and target of neurological remote monitoring but focuses on hardware data capture rather than patient-facing tracking apps.

Others

• Epilog (Epilepsy Foundation): The Epilepsy Foundation operates multiple epilepsy support tools including My Seizure Diary and education resources. While not a direct commercial competitor, it is an influential ecosystem player in the patient epilepsy community that affects Helpilepsy's channel for patient acquisition and clinician engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/helpilepsy
• LinkedInlinkedin.com/company/neuroventis

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helpilepsy